PDF(Pubmed)
Abstract：
Seasonal influenza significantly affects both health and economic costs in children and adults. This narrative review summarizes published cost-effectiveness analyses (CEAs) of cell-based influenza vaccines in children and adults <65 years of age, critically assesses the assumptions and approaches used in these analyses, and considers the role of cell-based influenza vaccines for children and adults. CEAs from multiple countries demonstrated the cost-effectiveness of cell-based quadrivalent influenza vaccines (QIVc) compared with egg-based trivalent/quadrivalent influenza vaccines (TIVe/QIVe). CEA findings were consistent across models relying on different relative vaccine effectiveness (rVE) estimate inputs, with the rVE of QIVc versus QIVe ranging from 8.1% to 36.2% in favor of QIVc. Across multiple scenarios and types of analyses, QIVc was consistently cost-effective compared with QIVe, including in children and adults across different regions of the world.
摘要：
季节性流感显著影响儿童和成人的健康和经济成本。这篇叙述性综述总结了已发表的65岁以下儿童和成人基于细胞的流感疫苗的成本效益分析（CEA）。批判性地评估这些分析中使用的假设和方法，并考虑了基于细胞的流感疫苗对儿童和成人的作用。来自多个国家的CEA证明了基于细胞的四价流感疫苗（QIVc）与基于鸡蛋的三价/四价流感疫苗（TIVe/QIVe）相比的成本效益。CEA的结果在依赖于不同相对疫苗有效性(rVE)估计输入的模型中是一致的，QIVc与QIVe的rVE范围为8.1%至36.2%，有利于QIVc。跨多个场景和分析类型，与QIVe相比，QIVc始终具有成本效益，包括世界各地不同地区的儿童和成人。
